Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study
Authors:
- Boya GuoBGBoya Guo
- Sarah KnerrSKSarah Knerr
- Kathleen F. MittendorfKMKathleen F. Mittendorf
- Heather Spencer FeigelsonHFHeather Spencer Feigelson
- Frances L. LynchFLFrances L. Lynch
- Kristin R. MuessigKMKristin R. Muessig
- Sonia OkuyamaSOSonia Okuyama
- Jamilyn M. ZeppJZJamilyn M. Zepp
- David L. VeenstraDVDavid L. Veenstra
Open Access
- 30 August 2023
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (18) , 19112-19125
Abstract
Background: Genetic testing can identify cancer risk early, enabling prevention and early detection. We describe use of risk management interventions following genetic testing in the Cancer Health Assessment Reaching Many (CHARM) study. CHARM assessed risk and provided genetic testing to low income, low literacy, and other underserved populations that historically face barriers to accessing cancer genetic services. Methods: CHARM was implemented in Kaiser Permanente Northwest (KPNW) and Denver Health (DH) between 2018 and 2020. We identified post-testing screening (mammography, breast MRI, colonoscopy) and surgical (mastectomy, oophorectomy) procedures using electronic health records. We examined utilization in participants who did and did not receive actionable risk management recommendations from study genetic counselors following national guidelines. Results: CHARM participants were followed for an average of 15.4 months (range: 0.4-27.8 months) after results disclosure. Less than 2% (11/680) received actionable risk management recommendations (i.e., could be completed in the initial years following testing) based on their test result. Among those who received actionable recommendations, risk management utilization was moderate (54.5%, 6/11 completed any procedure) and varied by procedure (mammogram: 0/3; MRI: 2/4; colonoscopy: 4/5; mastectomy: 1/5; oophorectomy: 0/3). Cancer screening and surgery procedures were rare in participants without actionable recommendations. Conclusion: Though the number of participants who received actionable risk management recommendations was small, our results suggest that implementing CHARM's risk assessment and testing model increased access to evidence-based genetic services and provided opportunities for patients to engage in recommended preventive care, without encouraging risk management overuse.Keywords
Funding Information
- National Human Genome Research Institute (U01HG007292, U24HG007307)
This publication has 36 references indexed in Scilit:
- Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™)Genetics in Medicine, 2019
- The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult PatientsAnnals of Internal Medicine, 2017
- Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch SyndromeJournal of Clinical Oncology, 2017
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Racial Disparities in Screening Mammography in the United States: A Systematic Review and Meta-analysisJournal of the American College of Radiology, 2017
- The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populationsCancer Causes & Control, 2016
- Screening for Cancer Genetic Syndromes With a Simple Risk-Assessment Tool in a Community-Based Open-Access Colonoscopy PracticeAmerican Journal of Gastroenterology, 2016
- Concerns About Cancer Risk and Experiences With Genetic Testing in a Diverse Population of Patients With Breast CancerJournal of Clinical Oncology, 2015
- Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal CancerAmerican Journal of Gastroenterology, 2014
- Models of genetic susceptibility to breast cancerOncogene, 2006